Rapid Therapeutic Science Laboratories, Inc is focused on developing potential commercial opportunities which involve the rapid application of therapeutics using inhaler technology. The Company is also focusing on manufacturing its own branded metered dose inhaler (MDI) under the inhaler brand name.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	85.73K 75.48K 69.62K 65.11K 122K 8.08M 124K 837K 324K 3.99M 322K 315K 13.87M	P/E 2021	-16.6x	P/E 2022	-3.24x
Enterprise Value	3.92M 3.45M 3.18M 2.97M 5.57M 369M 5.68M 38.22M 14.8M 182M 14.7M 14.39M 634M	EV / Sales 2021	93,978,853,933x	EV / Sales 2022	-
Free-Float	100%	Yield 2021 *	-	Yield 2022	-

15/08/23	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
12/05/23	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
31/03/23	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
30/03/23	Rapid Therapeutic Science Laboratories, Inc. Auditor Raises 'Going Concern' Doubt	CI
11/11/22	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
12/08/22	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI
31/05/22	Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.35 million in funding	CI
11/05/22	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
17/03/22	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
16/03/22	Rapid Therapeutic Science Laboratories, Inc. Auditor Raises 'Going Concern' Doubt	CI
28/01/22	Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.4 million in funding	CI
18/01/22	Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.15375 million in funding from Sixth Street Lending, LLC	CI
11/11/21	Rapid Therapeutics Science Laboratories Announces Launch of its New Facility Located in Addison, Tex	CI

06/12/23	Rapid Therapeutic Science Laboratories : Change in Certifying Accountants - Form 8-K	PU
31/03/23	RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
21/03/23	White House Office of Management and Budget review on Cannabis-Derived Products confirms Rapid Therapeutic Science Laboratories’ Long-Term Strategy	AQ
13/12/22	Rapid Therapeutic Science Laboratories Updates Patents	AQ
11/11/22	RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ

Manager	Title	Age	Since
Donal Schmidt CEO	Chief Executive Officer	65	15/11/2019
D. Watler DFI	Director of Finance/CFO	77	15/11/2019

Director	Title	Age	Since
D. Watler BRD	Director/Board Member	77	15/11/2019
Donal Schmidt BRD	Director/Board Member	65	15/11/2019

Rapid Therapeutic Science Laboratories, Inc. Stock Other OTC

Stocks

RTSL

US7534311052

Pharmaceuticals

Valuation: Rapid Therapeutic Science Laboratories, Inc.

Latest news : Rapid Therapeutic Science Laboratories, Inc.

Press Releases: Rapid Therapeutic Science Laboratories, Inc.

Managers and Directors: Rapid Therapeutic Science Laboratories, Inc.

Alternative Medicine

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC.	-.--%	-7.81%	-	-	1.9K
YUNNAN BAIYAO GROUP CO.,LTD	-1.01%	-3.60%	-14.89%	-9.93%	12.49B
BEIJING TONGRENTANG CO., LTD	-2.80%	-4.14%	-36.90%	-57.71%	4.62B
DONG-E-E-JIAO CO., LTD.	-1.35%	-7.59%	-16.86%	-7.35%	4.18B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-2.06%	+1.87%	+7.86%	-40.60%	3.82B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+0.42%	+0.53%	+14.94%	-15.07%	3.78B
HUBEI JUMPCAN PHARMACEUTICAL CO., LTD.	+2.83%	+2.29%	-3.35%	-5.02%	3.64B
TASLY PHARMACEUTICAL GROUP CO., LTD	-0.43%	-2.06%	-11.59%	-2.20%	3.03B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-1.37%	-1.95%	-6.91%	-25.22%	2.34B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	-1.15%	-3.23%	-12.43%	+30.20%	1.64B
Average	-0.69%	-1.56%	-8.90%	-14.77%	4.39B
Weighted average by Cap.	-0.85%	-1.78%	-10.74%	-16.90%

	2021	2022
Net sales	0 0 0 0 0 0.05 0 0.01 0 0.02 0 0 0.09	-
Net income	-2.87M -2.52M -2.33M -2.18M -4.08M -270M -4.16M -27.99M -10.84M -133M -10.77M -10.53M -464M	-1.79M -1.58M -1.46M -1.36M -2.55M -169M -2.6M -17.51M -6.78M -83.45M -6.74M -6.59M -290M
Net Debt	1.79M 1.58M 1.46M 1.36M 2.55M 169M 2.6M 17.5M 6.78M 83.37M 6.73M 6.59M 290M	3.83M 3.37M 3.11M 2.91M 5.45M 361M 5.55M 37.38M 14.48M 178M 14.38M 14.07M 620M